BUSULFANUM
Myelodysplastic Syndrome With Excess Blasts-1
Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Myelodysplastic Syndrome With Excess Blasts-1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclosporin A Singapore Eye Research Institute | Phase 4 | B |
METHOTREXATE Fred Hutchinson Cancer Center | Phase 2 | B |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | B |
TACROLIMUS Fred Hutchinson Cancer Center | Phase 2 | B |
View all 13 →
Same molecule, other indications
BUSULFANUM is also rated in:
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →